| Scrip Code | 530239 |
|---|---|
| NSE Symbol | SUVEN |
| MSEI Symbol | NOTLISTED |
| ISIN | INE495B01038 |
| Name of company | SUVEN LIFE SCIENCES LIMITED |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2026 |
| Date of end of financial year | 31-03-2027 |
| Date of board meeting when results were approved | 06-08-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 30-07-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | First quarter |
| Nature of report standalone or consolidated | Standalone |
| Whether results are audited or unaudited for the quarter ended | Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | |
| Segment Reporting | Single segment |
| Description of single segment | The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented |
| Start date and time of board meeting | 06-08-2026 11:30:00 |
| End date and time of board meeting | 06-08-2026 12:30:00 |
| Whether cash flow statement is applicable on company | |
| Type of cash flow statement | |
| Declaration of unmodified opinion or statement on impact of audit qualification | Not applicable |
| Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? | Yes |
| No. of times funds raised during the quarter | 1 |
| Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? | No |
| Nil | |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-04-2026 | 01-04-2026 |
| B | Date of end of reporting period | 30-06-2026 | 30-06-2026 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| 1 | Income | ||
| Revenue from operations | 356.58 | 356.58 | |
| Other income | 752.36 | 752.36 | |
| Total income | 1,108.94 | 1,108.94 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 0.00 | 0.00 |
| (b) | Purchases of stock-in-trade | 0.00 | 0.00 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | 0.00 | 0.00 |
| (d) | Employee benefit expense | 728.18 | 728.18 |
| (e) | Finance costs | 47.61 | 47.61 |
| (f) | Depreciation, depletion and amortisation expense | 215.51 | 215.51 |
| (f) | Other Expenses | ||
| 1 | R & D Expenses | 1,275.60 | 1,275.60 |
| 2 | Other Expenses | 453.95 | 453.95 |
| Total other expenses | 1,729.55 | 1,729.55 | |
| Total expenses | 2,720.85 | 2,720.85 | |
| 3 | Total profit before exceptional items and tax | (1,611.91) | (1,611.91) |
| 4 | Exceptional items | 0.00 | 0.00 |
| 5 | Total profit before tax | (1,611.91) | (1,611.91) |
| 6 | Tax expense | ||
| 7 | Current tax | 0.00 | 0.00 |
| 8 | Deferred tax | 0.00 | 0.00 |
| 9 | Total tax expenses | 0.00 | 0.00 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | (1,611.91) | (1,611.91) |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 |
| 16 | Total profit (loss) for period | (1,611.91) | (1,611.91) |
| 17 | Other comprehensive income net of taxes | (5.55) | (5.55) |
| 18 | Total Comprehensive Income for the period | (1,617.46) | (1,617.46) |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | |||
| Total profit or loss, attributable to non-controlling interests | |||
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | |||
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | |||
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 2,639.93 | 2,639.93 | |
| Face value of equity share capital | 1 | 1 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | -0.61 | -0.61 | |
| Diluted earnings (loss) per share from continuing operations | -0.61 | -0.61 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | -0.61 | -0.61 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | -0.61 | -0.61 | |
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | 1. The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 06, 2026. The financial results for the quarter ended June 30, 2026 has been reviewed by our statutory auditors and issued unmodified reports thereon. 2. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. 3. The consolidated financial results include the results of the wholly Owned Subsidiary, Suven Neurosciences, Inc. 4. The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented. 5.1 The Company implemented SLSL Employee Stock Option Scheme 2020 (ESOP) for eligible employees, 1,33,200 stock options were granted on May 13,2026 by the Nomination & Remuneration Committee. 5.2 ESOP: for the quarter ended June 30, 2026, the Company has recognized an employee benefit expense (EBP) of Rs. 145.54 lakhs in accordance with Ind AS 102 – Share-based Payment. 5.3 During the quarter ended June 30, 2026, the Company has allotted 2,71,970 equity shares of Rs.1 each, pursuant to the exercise of stock options by the employees of the company under Employee Stock Options Scheme 2020. 6. Preferential Issue: The Board of Directors of the Company has approved the issue of 6,40,02,999 convertible warrants on a preferential basis to 23 allottees in its meeting held on 13th May, 2025, in accordance with the provisions of the Companies Act, 2013 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Subsequently, shareholders of the Company approved the issue of convertible warrants in their meeting held on 05th June, 2025. Each warrant is convertible into one equity share of face value Rs.1 at an exercise price of Rs.134 per share, within a period of 18 months from the date of allotment. As on 30 June 2026, the company has received the entire amount of Rs.85,764.02 lakhs from the warrant holders, out of which an amount of Rs.9,331.49 lakhs was received during the quarter in respect of 1,85,70,133 warrants, for which allotment is pending as on reporting date. Summary of Utilisation of Proceeds of Preferential issue as on 30.06.2026 Particulars Amount Rs. in Lakhs Amount Received through Preferential Issue 85,764.02 Less: Amount Utilised 40,950.29 Balance Amount 44,813.73 7. The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to third quarter of the financial year. |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-04-2026 | 01-04-2026 | |||||
| Date of end of reporting period | 30-06-2026 | 30-06-2026 | |||||
| Whether results are audited or unaudited | Unaudited | Unaudited | |||||
| Nature of report standalone or consolidated | Standalone | Standalone | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| Total Segment Revenue | |||||||
| Less: Inter segment revenue | |||||||
| Revenue from operations | |||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| Total Profit before tax | |||||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | |||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| Total Segment Asset | |||||||
| Un-allocable Assets | null | null | |||||
| Net Segment Asset | null | null | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| Total Segment Liabilities | |||||||
| Un-allocable Liabilities | null | null | |||||
| Net Segment Liabilities | null | null | |||||
| Disclosure of notes on segments | |||||||
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-04-2026 | 01-04-2026 |
| B | Date of end of reporting period | 30-06-2026 | 30-06-2026 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Items that will not be reclassified to profit or loss | (5.55) | (5.55) |
| Total Amount of items that will not be reclassified to profit and loss | (5.55) | ||
| 2 | Income tax relating to items that will not be reclassified to profit or loss | 0.00 | 0.00 |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| Total Amount of items that will be reclassified to profit and loss | |||
| 4 | Income tax relating to items that will be reclassified to profit or loss | 0.00 | 0.00 |
| 5 | Total Other comprehensive income | (5.55) | (5.55) |
| Mode of Fund Raising | Preferential Issues |
|---|---|
| Description of mode of fund raising (Applicable in case of others is selected) | |
| Date of Raising Funds | 03-07-2025 |
| Amount Raised | 85,764.02 |
| Report filed for Quarter ended | 30-06-2026 |
| Monitoring Agency | Applicable |
| Monitoring Agency Name, if applicable | CRISIL Ratings Limited |
| Is there a Deviation / Variation in use of funds raised | No |
| If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders | |
| If Yes, Date of shareholder Approval | |
| Explanation for the Deviation / Variation | Not Applicable |
| Comments of the Audit Committee after review | Nil |
| Comments of the auditors, if any | Not Applicable |
| Sr. | Original Object | Modified Object, if any | Original Allocation | Modified allocation, if any | Funds Utilised | Amount of Deviation/Variation for the quarter according to applicable object | Remarks if any |
| 1 | Expenses towards the conduct of clinical development of molecules in research pipeline through Suven Neurosciences, Inc. an overseas wholly owned subsidiary of the Company | Not Applicable | 40,000.00 | 0.00 | 27,242.87 | 0.00 | The difference amount (Original Allocation - Funds Utilised) of Rs. 12,757.13 is yet to be utilized as on 30-06-2026 |
| 2 | Expenses towards Drug Discovery Research & Development (R&D) | Not Applicable | 13,000.00 | 0.00 | 5,187.23 | 0.00 | The difference amount (Original Allocation - Funds Utilised) of Rs. 7,812.77 is yet to be utilized as on 30-06-2026 |
| 3 | Expenses towards new R&D Centre with all requisite infrastructure and equipments (CAPEX) | Not Applicable | 20,000.00 | 0.00 | 4,960.94 | 0.00 | The difference amount (Original Allocation - Funds Utilised) of Rs. 15,039.06 is yet to be utilized as on 30-06-2026 |
| 4 | Expenses towards General Corporate purposes | Not Applicable | 12,764.02 | 0.00 | 3,559.24 | 0.00 | The difference amount (Original Allocation - Funds Utilised) of Rs. 9,204.78 is yet to be utilized as on 30-06-2026 |
| Name of signatory | M. Mohan Kumar |
| Designation of person | Chief Financial Officer |
| Place | Hyderabad |
| Date | 06-08-2026 |